Abstract
Background: Chronic respiratory diseases (CRDs) are increasing in prevalence, as reported by the World Health Organization (WHO). Patients with CRDs usually require co-administration of multiple drugs due to the complex pathogenic mechanisms of CRDs and the existence of concomitant diseases. Polypharmacy (co-administration of more than four medications) is the main risk factor of the occurrence of drug-drug interactions (DDIs) that may lead to reducing treatment efficacy and/or increasing adverse effects.
Methods: This literature-based review focuses on metabolism-based DDIs, the most prevalent DDIs responsible for difficulties in therapeutic management in patients with CRDs.
Results: Clinically relevant metabolism-based DDIs occur between drugs used for the treatment of respiratory diseases (corticosteroids, orally inhaled bronchodilators, methylxanthines, anti-leukotrienes, antimicrobials, endothelin receptor antagonists, phosphodiesterase inhibitors, antitussives, and antineoplastic agents) and drugs affecting cytochrome P450 (CYP) (inducers and inhibitors). Considering alternative therapies, adjusting medication doses, or monitoring patients during treatment are recommended to prevent the harmful consequences of these interactions.
Conclusion: Providing information on clinically relevant interactions of drugs more likely prescribed in daily practices of physicians is essential to improve patient safety. A list of known metabolism-based interactions of drugs affecting the respiratory systems should be available for physicians engaged in the treatment of CRDs.
Keywords: Chronic respiratory diseases, cytochrome P450, drug-drug interactions, enzyme inducers, enzyme inhibitors, metabolism, respiratory system, uridine glucuronosyl transferases.
Graphical Abstract
Current Drug Metabolism
Title:Metabolism-based Drug-drug Interactions in Patients with Chronic Respiratory Diseases: A Review Focusing on Drugs Affecting the Respiratory System
Volume: 21 Issue: 9
Author(s): Shadi Baniasadi*
Affiliation:
- Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran,Iran
Keywords: Chronic respiratory diseases, cytochrome P450, drug-drug interactions, enzyme inducers, enzyme inhibitors, metabolism, respiratory system, uridine glucuronosyl transferases.
Abstract:
Background: Chronic respiratory diseases (CRDs) are increasing in prevalence, as reported by the World Health Organization (WHO). Patients with CRDs usually require co-administration of multiple drugs due to the complex pathogenic mechanisms of CRDs and the existence of concomitant diseases. Polypharmacy (co-administration of more than four medications) is the main risk factor of the occurrence of drug-drug interactions (DDIs) that may lead to reducing treatment efficacy and/or increasing adverse effects.
Methods: This literature-based review focuses on metabolism-based DDIs, the most prevalent DDIs responsible for difficulties in therapeutic management in patients with CRDs.
Results: Clinically relevant metabolism-based DDIs occur between drugs used for the treatment of respiratory diseases (corticosteroids, orally inhaled bronchodilators, methylxanthines, anti-leukotrienes, antimicrobials, endothelin receptor antagonists, phosphodiesterase inhibitors, antitussives, and antineoplastic agents) and drugs affecting cytochrome P450 (CYP) (inducers and inhibitors). Considering alternative therapies, adjusting medication doses, or monitoring patients during treatment are recommended to prevent the harmful consequences of these interactions.
Conclusion: Providing information on clinically relevant interactions of drugs more likely prescribed in daily practices of physicians is essential to improve patient safety. A list of known metabolism-based interactions of drugs affecting the respiratory systems should be available for physicians engaged in the treatment of CRDs.
Export Options
About this article
Cite this article as:
Baniasadi Shadi *, Metabolism-based Drug-drug Interactions in Patients with Chronic Respiratory Diseases: A Review Focusing on Drugs Affecting the Respiratory System, Current Drug Metabolism 2020; 21 (9) . https://dx.doi.org/10.2174/1389200221999200820164038
DOI https://dx.doi.org/10.2174/1389200221999200820164038 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bacteriophage - A Common Divergent Therapeutic Approach for Alzheimer's Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Perspectives of Activated Protein C in the Vasculature: Update on Proposed Roles of the Protein C Pathway
Current Genomics Seasonal and Perennial Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Chios Gum Mastic: A Review of its Biological Activities
Current Medicinal Chemistry A Viewpoint on Angiotensin-Converting Enzyme 2, Anti-Hypertensives and Coronavirus Disease 2019 (COVID-19)
Infectious Disorders - Drug Targets Steroids and Vasopressor-Resistant Hypotension in Preterm Infants
Current Pediatric Reviews Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease
Current Medicinal Chemistry Comparative Efficacy and Safety Study of Darbepoetin Alfa <i>versus</i> Epoetin Alfa in Management of Anemia Associated with ESRD in Egyptian Hemodialysis Patients
Current Drug Safety Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Are Bacteriocins Underexploited? NOVEL Applications for OLD Antimicrobials
Current Pharmaceutical Biotechnology Serum Interleukin Levels and Insulin Resistance in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets Dietary Interventions in Children with Autism Spectrum Disorders - An Updated Review of the Research Evidence
Current Clinical Pharmacology Implantable Cardioverter-Defibrillators in Patients with ESRD: Complications, Management, and Literature Review
Current Cardiology Reviews Recent Trends in the Pharmacological Activity of Isoprenyl Phenolics
Current Medicinal Chemistry Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets Inflammation and Cancer: In Medio Stat Nano
Current Medicinal Chemistry Chemotherapy In Japanese Encephalitis: Are We There Yet?
Infectious Disorders - Drug Targets Withdrawal Notice: Therapeutic Options for Treatment of COVID-19: A Review from Repurposed Drugs to New Drug Targets
Current Drug Targets A Review of Research Progress on <i>Agathis dammara</i> and its Application Prospects for Cardiovascular Diseases and Fatty Liver Disease
Mini-Reviews in Medicinal Chemistry Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery